NCT05162118View on ClinicalTrials.gov

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

March 22, 2025

Study Completion Date

December 22, 2025

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab

Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.

Trial Locations (1)

310003

RECRUITING

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER